ImprimisRx offers a look at three new products in the pipeline
November 14, 2021
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
March 22, 2022
Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.
November 14, 2021
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
November 01, 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
June 30, 2021
FDA approval of teprotumumab as therapeutic offers hope for patients.
April 14, 2021
Sublingual troche sedation represents attractive anesthesia option for specific subset of patients with cataracts.
April 02, 2021
Study highlights role of demographic and socioeconomic characteristics in treatment.
March 02, 2021
Autologous serum eye drops and blood products offer hope to patients.
January 27, 2021
Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.
November 16, 2020
Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population
November 13, 2020
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.